Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE